|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 875.70 DKK | -1.07% |
|
-6.56% | +25.57% |
| 09:12am | NOVO NORDISK : Gets a Neutral rating from Berenberg | ZD |
| Sep. 05 | Health Care Declines as Risk Aversion Weighs - Health Care Roundup | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
| Capitalization | 3,925B 585B | P/E ratio 2024 * |
38.9x | P/E ratio 2025 * | 30.6x |
|---|---|---|---|---|---|
| Enterprise value | 3,929B 585B | EV / Sales 2024 * |
13.5x | EV / Sales 2025 * | 11.2x |
| Free-Float |
70.25% | Yield 2024 * |
1.29% | Yield 2025 * | 1.7% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | -1.30% | ||
| 1 week | -4.01% | ||
| Current month | -5.64% | ||
| 1 month | +4.30% | ||
| 3 months | -5.45% | ||
| 6 months | +3.53% | ||
| Current year | +26.80% |
1 week
879.80
942.40
1 month
820.00942.40
Current year
688.801 033.20
1 year
614.301 033.20
3 years
302.201 033.20
5 years
164.351 033.20
10 years
109.101 033.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Kasim Kutay
BRD | Director/Board Member | 59 | 17-03-22 |
Helge Lund
CHM | Chairman | 62 | 17-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 208 M€ | +13.88% | - | |
| 10.45% | 4 M€ | +13.44% | ||
| 5.40% | 18 M€ | +7.76% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.36% | -4.01% | +33.76% | +181.19% | 583B | ||
| -3.55% | -2.92% | +63.52% | +251.69% | 822B | ||
| -1.42% | +0.46% | +2.68% | -5.74% | 397B | ||
| -2.11% | -1.19% | +32.01% | +72.78% | 341B | ||
| +2.41% | +0.96% | +10.31% | +53.49% | 301B | ||
| +0.12% | -5.53% | +16.80% | +47.37% | 256B | ||
| -0.78% | -3.22% | +8.78% | -24.28% | 262B | ||
| -1.21% | -2.95% | +12.67% | +18.64% | 236B | ||
| -1.90% | -2.01% | +27.70% | +43.29% | 174B | ||
| +0.42% | -0.73% | -19.42% | -39.13% | 162B | ||
| Average | -0.28% | -2.11% | +18.88% | +59.93% | 353.35B | |
| Weighted average by Cap. | -0.27% | -2.29% | +27.80% | +102.57% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 290B 43.23B | 349B 52B |
| Net income | 102B 15.17B | 128B 19.05B |
| Net Debt | 4.63B 690M | -17.33B -2.58B |
More financial data
* Estimated data
Employees
69,260
Sector
Pharmaceuticals
Calendar
2024-11-06
- Q3 2024 Earnings Release
Related indices
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-06 | 878.00 kr | -0.81% | 129,320 |
| 24-09-05 | 885.20 kr | -2.16% | 2,343,150 |
| 24-09-04 | 904.70 kr | -2.45% | 1,873,627 |
| 24-09-03 | 927.40 kr | -0.18% | 1,809,305 |
| 24-09-02 | 929.10 kr | -0.96% | 1,275,996 |
Delayed Quote Nasdaq Copenhagen, September 05, 2024 at 11:20 am EDT
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
885.20DKK
Average target price
969.52DKK
Spread / Average Target
+9.53%
- Stock Market
- Equities
- NOVO B Stock
